SCO-201

SCO-201 is an investigational **small-molecule** pyrazolo[3,4-d]pyrimidine derivative being developed by **Scandion Oncology** for **chemotherapy-resistant cancer**. It is designed to reverse multidrug resistance by **competitively inhibiting the breast cancer resistance protein transporter ABCG2**, also known as **BCRP**, an ATP-binding cassette efflux pump that can expel anticancer agents from tumor cells. Preclinical reports describe SCO-201 as a **potent and selective BCRP inhibitor** that can restore sensitivity to agents such as **SN-38**, the active metabolite of irinotecan, in resistant cancer cell models, with limited reported off-target activity on cytochrome P450 enzymes. The program appears to be at the **preclinical or early in-development** stage, and no approved brand name or established generic name has been identified from the provided context.